Trinity Biotech Files 6-K Report
Ticker: TRIB · Form: 6-K · Filed: Oct 2, 2024 · CIK: 888721
| Field | Detail |
|---|---|
| Company | Trinity Biotech PLC (TRIB) |
| Form Type | 6-K |
| Filed Date | Oct 2, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 6-K, foreign-private-issuer, reporting
TL;DR
Trinity Biotech dropped a 6-K filing on Oct 2nd covering Q2. Standard update.
AI Summary
Trinity Biotech plc filed a 6-K report on October 2, 2024, for the period ending June 30, 2024. The filing is a report of a foreign private issuer and includes information related to their business operations and financial reporting.
Why It Matters
This filing provides an update on Trinity Biotech's operations and financial status as a foreign private issuer, which is important for investors tracking the company's performance.
Risk Assessment
Risk Level: low — This filing is a routine report of a foreign private issuer and does not contain significant new financial information or material events.
Key Players & Entities
- TRINITY BIOTECH PLC (company) — Registrant
- 0001178913-24-003210 (filing_id) — Accession Number
- 20241002 (date) — Filing Date
- 20240630 (date) — Reporting Period End Date
FAQ
What type of report is Trinity Biotech plc filing?
Trinity Biotech plc is filing a Form 6-K, which is a Report of Foreign Private Issuer.
What is the reporting period for this 6-K filing?
The conformed period of report is June 30, 2024.
When was this 6-K filing submitted to the SEC?
The filing was submitted on October 2, 2024.
What is the company's principal executive office address?
The principal executive office is located at IDA Business Park, Bray, Co. Wicklow, Ireland.
What is Trinity Biotech's Standard Industrial Classification code?
Trinity Biotech's SIC code is 2835, for In Vitro & In Vivo Diagnostic Substances.
Filing Stats: 343 words · 1 min read · ~1 pages · Grade level 13.6 · Accepted 2024-10-02 11:22:41
Filing Documents
- zk2432086.htm (6-K) — 19KB
- exhibit_99-1.htm (EX-99.1) — 1759KB
- exhibit_99-2.htm (EX-99.2) — 56KB
- 0001178913-24-003210.txt ( ) — 10302KB
- trib-20240630.xsd (EX-101.SCH) — 177KB
- trib-20240630_cal.xml (EX-101.CAL) — 59KB
- trib-20240630_def.xml (EX-101.DEF) — 257KB
- trib-20240630_lab.xml (EX-101.LAB) — 1582KB
- trib-20240630_pre.xml (EX-101.PRE) — 403KB
- zk2432086_htm.xml (XML) — 2148KB
Management's Discussion and Analysis of Results of Operations, Liquidity and Cash Flows
Management's Discussion and Analysis of Results of Operations, Liquidity and Cash Flows
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TRINITY BIOTECH PLC (Registrant) By: /s/ Louise Tallon Louise Tallon Chief Financial Officer Date: October 2, 2024